In May 2002, Medscape reported on the Medical Therapy of Prostatic Symptoms (MTOPS) Trial, which suggested a definite benefit to combining finasteride and doxazosin for the treatment of benign prostatic hypertrophy (BPH). But now, results of the Prospective European Doxazosin and Combination Therapy (PREDICT) trial, reported in the January issue of Urology, suggests the opposite: finasteride was no better than placebo when added to doxazosin.
However, there are significant differences between the trials, including size and end points. “Doxazosin was effective in improving urinary symptoms and urinary flow rate in men with BPH, and was more effective than finasteride alone or placebo,” write Roger S. Kirby and colleagues from the PREDICT Study Investigators. “The addition of finasteride did not provide further benefit to that achieved with doxazosin alone.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!